Economic Analysis of Antihypertensive Agents in Treating Patients with Essential Hypertension
|
Accession number;03A0530036
|
| Title;Economic Analysis of Antihypertensive Agents in Treating Patients with Essential Hypertension |
| Author;
SAITO IKUO
(Keio Univ., Health Center, JPN)
KOBAYASHI MAKOTO
(Kurekonrisachi&konsarutingu Iryoasesumentokenkyubu)
SARUTA TAKAO
(Sch. of Med., Keio Univ.)
|
Journal Title;Journal of Clinical Therapeutics & Medicines
|
Journal Code:Y0906A
|
ISSN:0910-8211
|
|
VOL.19;NO.7;PAGE.777-788(2003)
|
| Figure&Table&Reference;FIG.3, TBL.5, REF.34 |
| Pub. Country;Japan |
| Language;Japanese |
| Abstract;The cost-effectiveness of antihypertensive agents in Japan was determined by analysis of the relationship between prolongation of "survival time" and "cost" in patients with essential hypertension using an economic analysis technique for pharmaceuticals. In particular, angiotensin II (AII) receptor antagonists were examined for their cost-effectiveness. First, we established a Markov model for the treatment and prognosis of moderately hypertensive patients who had no past history of cardiovascular diseases. Based on the Markov model, essential hypertension patients at the age of 55 with diastolic blood pressure (DBP) of 100mmHg were analyzed to identify the relationship between expected survival time and expected cost, classified by the degree of decreases in DBP and daily drug price, and the data were plotted (Generalized cost-effectiveness analysis). Next, the cost-effectiveness of AII receptor antagonists was calculated based on comparative data from the USA on 4 AII eceptor antagonists, including olmesartan. The analysis was made from the payer's perspective. The effectiveness index was set as survival time, and analyzed costs included direct medical costs and cost of care. Costs and effectiveness were discounted at an annual rate of 3% for evaluation as the present value. Our generalized cost-effectiveness analysis showed that by decreasing the DBP by 2mmHg, survival time was confirmed to be prolonged by about 0.05 years per patient. Expected costs were reduced by about 200,000yen. Similar results were obtained in the range of expected daily drug price. In comparison of lifetime analysis of both sexes between the drugs on the assumption that the drug price of olmesartan is the same as that of losartan, olmesartan was found to prolong survival time per patient by 0.087 to 0.215 years and reduce expected costs by 146,000 to 716,000yen in comparison with losartan and valsartan.... (author abst.) |
|
|
|
Related Articles;
|
|
